

11 January 2022

**Diaceutics PLC**

("Diaceutics" or "the Company")

**Directorate Change**

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, is pleased to announce the appointment of Nick Roberts as Chief Financial Officer and director of the Board, effective as of mid-March 2022. At the same time, current Chief Financial Officer Philip White will step down from his role and the Board to pursue new business opportunities. Philip will remain with the business until the end of April to provide for an orderly handover of duties.

Nick is a highly experienced senior finance professional with a track record of managing and developing finance functions and governance structures in high growth AIM-listed healthcare and technology companies with global customer bases.

He is currently Head of Group Reporting at AIM-quoted Ergomed plc, a full-service pharmacovigilance and specialist clinical trial service provider to the pharmaceutical and biotechnology industries with over 1,250 employees and a market capitalisation of c. £640m. During his tenure, Nick has developed and managed the day-to-day group finance reporting requirements for Ergomed plc and has overseen the roll-out of several governance framework and reporting projects, including the financial integration of two US business acquisitions. Prior to this, Nick was Group Financial Controller at AIM-quoted Ceres Power Holdings plc, a fuel cell and electrochemical technology development company, leading the development of the finance function to accommodate a period of considerable commercial and financial growth over four years.

Nick is a Fellow Chartered Accountant with the Institute of Chartered Accountants in England and Wales (ICAEW) and holds a bachelor's degree in Accounting and Finance from the University of Southampton.

**Peter Keeling, CEO and Founder of Diaceutics PLC, commented:**

*"I am delighted to welcome Nick to Diaceutics. Nick's background working with high-growth, platform-oriented businesses across tech and pharma makes him an excellent fit, and his experience leading finance functions to accommodate significant year-on-year revenue growth will serve as a real asset to us. I look forward to welcoming Nick to the team as we look to take Diaceutics to its next level of growth and accelerate the transformation of our business model.*

*"Equally, I would like to wholeheartedly thank Philip for his contribution to Diaceutics, having led us through a successful IPO and played a key role in the first few years as a public company. We wish him all the best in his future business."*

**Information required to be disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:**

Nicholas Stewart Roberts, aged 39, has no current or previous directorships or partnerships within the past five years.

Save for the information disclosed above, there is no other information to be disclosed under Schedule 2(g) of the AIM Rules.

Nick Roberts does not hold any ordinary shares in the Company.

**Enquiries:**

**Diaceutics PLC**

Peter Keeling, Chief Executive Officer

Via Alma PR

**Stifel Nicolaus Europe Limited (Nomad & Broker)**

Ben Maddison, Stewart Wallace, Nick Adams

Tel: +44 (0)20 7710 7600

**Alma PR**

Caroline Forde, Kieran Breheny, Matthew Young

Tel: +44(0)20 3405 0205

diaceutics@almapr.co.uk

**About Diaceutics**

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOABKKBQFBKDCDD